ES2682670T3 - Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas - Google Patents

Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas Download PDF

Info

Publication number
ES2682670T3
ES2682670T3 ES12773653.6T ES12773653T ES2682670T3 ES 2682670 T3 ES2682670 T3 ES 2682670T3 ES 12773653 T ES12773653 T ES 12773653T ES 2682670 T3 ES2682670 T3 ES 2682670T3
Authority
ES
Spain
Prior art keywords
positive bacteria
detection
treatment
gram positive
gram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12773653.6T
Other languages
English (en)
Inventor
Vincent A. Fischetti
Jonathan SCHMITZ
Daniel GILMER
Chad Euler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Application granted granted Critical
Publication of ES2682670T3 publication Critical patent/ES2682670T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Una composición farmacéutica para uso para matar bacterias gram-positivas seleccionadas de cepas de Staphylococcus, cepas de Streptococcus, Listeria monocytogenes y Enterococcus faecalis en un método para tratar una infección por bacterias gram-positivas causada por dichas bacterias en un ser humano, que comprende un polipéptido de lisina aislado que comprende la secuencia de aminoácidos de SEQ ID NO:3 o variantes de esta que tienen al menos una identidad del 80% con el polipéptido de SEQ ID NO:3 y que es efectivo para matar a dichas bacterias gram-positivas.
ES12773653.6T 2011-04-21 2012-04-20 Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas Active ES2682670T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161477836P 2011-04-21 2011-04-21
US201161477836P 2011-04-21
PCT/US2012/034456 WO2012145630A2 (en) 2011-04-21 2012-04-20 Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria

Publications (1)

Publication Number Publication Date
ES2682670T3 true ES2682670T3 (es) 2018-09-21

Family

ID=47042182

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12773653.6T Active ES2682670T3 (es) 2011-04-21 2012-04-20 Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas

Country Status (12)

Country Link
US (7) US9034322B2 (es)
EP (2) EP3252155A1 (es)
JP (4) JP6139509B2 (es)
CN (4) CN108578685A (es)
AU (3) AU2012245357B2 (es)
CA (1) CA2833409A1 (es)
DK (1) DK2699253T3 (es)
ES (1) ES2682670T3 (es)
HK (2) HK1244503A1 (es)
IL (4) IL228869B (es)
MX (3) MX336427B (es)
WO (1) WO2012145630A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2981662C (en) 2011-01-14 2019-02-05 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
AU2012245391A1 (en) * 2011-04-21 2013-11-21 The Rockefeller University Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock
NL2007038C2 (en) * 2011-07-04 2013-01-07 Vereniging Voor Christelijk Hoger Onderwijs System and method for predicting the viability of a body tissue in a patient, and measuring device used therein.
ES2784136T3 (es) * 2012-05-09 2020-09-22 Contrafect Corp Combinaciones de lisina de bacteriófagos y antibióticos contra bacterias grampositivas
EP3513807A1 (en) * 2012-05-09 2019-07-24 Contrafect Corporation Biofilm prevention, disruption and treatment with bacteriophase lysin
CN104073478A (zh) * 2014-06-13 2014-10-01 上海交通大学 杀灭革兰氏阳性菌的酶抗生素及其制备、用途
CN106659748B (zh) 2014-06-26 2021-08-31 洛克菲勒大学 不动杆菌属溶素
CN104726439B (zh) * 2015-04-13 2017-11-14 武汉菲吉乐科生物科技有限公司 一种广谱的链球菌裂解酶及其应用
CN104805066B (zh) * 2015-05-18 2018-04-24 武汉菲吉乐科生物科技有限公司 一种葡萄球菌裂解酶及其应用
EP3328417A4 (en) * 2015-07-31 2019-02-06 The Regents of The University of California MYCOBACTERIUM LYSTEASE: A NEW TREATMENT AGAINST ACNE
EP3341013A4 (en) * 2015-09-13 2018-07-18 The Rockefeller University Clostridium difficile BACTERIOPHAGE LYSINS FOR DETECTION AND TREATMENT OF Clostridium difficile BACTERIA INFECTION
AU2016324307B2 (en) 2015-09-17 2021-10-21 Contrafect Corporation Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
EP3454888B1 (en) 2016-05-12 2021-02-24 Contrafect Corporation Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptides
JP2020527551A (ja) * 2017-07-10 2020-09-10 コントラフェクト コーポレイション 血液成分による溶菌タンパク質の抗菌活性の強化、並びにその方法及び使用
AU2019205388A1 (en) * 2018-01-05 2020-07-23 Azitra Inc Auxotrophic strains of Staphylococcus bacterium
WO2019165454A1 (en) * 2018-02-26 2019-08-29 Contrafect Corporation Modified plyss2 lysins and uses thereof
KR102073088B1 (ko) * 2018-06-04 2020-02-04 (주)인트론바이오테크놀로지 신규한 스트렙토코커스 수이스 박테리오파지 Str-SUP-2 및 이의 스트렙토코커스 수이스 균 증식 억제 용도
KR102073086B1 (ko) * 2018-06-04 2020-02-04 (주)인트론바이오테크놀로지 신규한 스트렙토코커스 수이스 박테리오파지 Str-SUP-1 및 이의 스트렙토코커스 수이스 균 증식 억제 용도
KR102073094B1 (ko) * 2018-06-04 2020-02-04 (주)인트론바이오테크놀로지 신규한 스트렙토코커스 수이스 박테리오파지 Str-SUP-3 및 이의 스트렙토코커스 수이스 균 증식 억제 용도
JP2021533828A (ja) * 2018-08-17 2021-12-09 ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company 微小液滴を使用する抗菌薬感受性検査
EP3864166A1 (en) 2018-10-12 2021-08-18 Quidel Corporation Extraction reagent for use in an assay for detection of group a streptococcus
WO2020198073A1 (en) * 2019-03-22 2020-10-01 Contrafect Corporation Method of treating infective endocarditis
AU2020256258A1 (en) * 2019-04-05 2021-11-04 Contrafect Corporation Lysins and derivatives thereof with bactericidal activity against Pseudomonas aeruginosa, in the presence of human serum
CN114025783A (zh) * 2019-04-11 2022-02-08 康特拉费克特公司 治疗和预防骨和关节感染的方法
AU2021275048A1 (en) * 2020-05-19 2023-02-02 Contrafect Corporation Modified PlySs2 lysins and antibiotic combinations for use against Gram-positive bacteria
US20220087266A1 (en) * 2020-09-22 2022-03-24 Mars, Incorporated Compositions and methods for controlling mycotoxin production
CN114480299B (zh) * 2020-10-27 2023-08-29 暨南大学 一种蜡样芽胞杆菌噬菌体及其应用
CN112760312B (zh) * 2021-01-20 2022-06-17 华中农业大学 一种裂解革兰氏阳性菌的裂解酶plyssX609及其应用
WO2023049747A1 (en) * 2021-09-22 2023-03-30 Elanco Us Inc. Streptococcus suis lytic enzyme compositions and methods of use thereof
KR20240015755A (ko) * 2022-07-26 2024-02-06 주식회사 인트론바이오테크놀로지 연쇄상구균에 대하여 용균 활성을 갖는 항균단백질
WO2024059184A1 (en) * 2022-09-16 2024-03-21 The Johns Hopkins University Machine learning systems and related aspects for the detection of disease states
CN116640754B (zh) * 2023-07-21 2023-10-10 临沂大学 一种链球菌前噬菌体裂解酶lys224及应用
CN117051043B (zh) * 2023-10-11 2024-01-30 圆因(北京)生物科技有限公司 一种基于环状rna编码耐甲氧西林金黄色葡萄球菌内溶素及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278378A (en) 1962-04-19 1966-10-11 Schindler Charles Alvin Staphylococcus-derived antibiotic
US3398056A (en) 1964-07-10 1968-08-20 Mead Johnson & Co Process for producing lysostaphin by fermentation
US3594284A (en) 1968-06-04 1971-07-20 Mead Johnson & Co Lysostaphin fermentation with accelerated time cycle
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE151286T1 (de) 1983-11-14 1997-04-15 Columbia Lab Inc Bioadhäsive mittel
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
WO1988002781A1 (en) 1986-10-08 1988-04-21 David Bernstein Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci
US4948580A (en) 1988-12-08 1990-08-14 E. R. Squibb & Sons, Inc. Muco-bioadhesive composition
JPH02258718A (ja) 1989-03-31 1990-10-19 Nippon Kayaku Co Ltd ペースト状基剤及び製剤
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5554380A (en) 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
US6254866B1 (en) 1997-10-31 2001-07-03 New Horizons Diagnostics Corporation Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract
US6264945B1 (en) 1997-10-31 2001-07-24 Vincent A Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US6248324B1 (en) 1997-10-31 2001-06-19 Vincent Fischetti Bacterial phage associated lysing enzymes for treating dermatological infections
US20060292135A1 (en) * 1997-10-31 2006-12-28 Lawrence Loomis Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
JP2002537350A (ja) 1999-02-25 2002-11-05 ニュー ホライズンズ ダイアグノスティックス インコーポレーティッド 連鎖球菌感染の予防的及び治療的な処置のための手段
CN1352567A (zh) * 1999-02-25 2002-06-05 新眼界诊断公司 预防性和治疗性治疗链球菌感染的方法
US6056955A (en) 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
AU2003291614A1 (en) 2002-05-17 2004-04-08 New Horizons Diagnostics Corporation Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis
US8326388B2 (en) 2002-10-31 2012-12-04 Toshiba Medical Systems Corporation Method and apparatus for non-invasive measurement of living body characteristics by photoacoustics
KR20050086427A (ko) * 2002-11-07 2005-08-30 시너지 아메리카 인코포레이티드 폐렴균의 감염 치료 또는 예방용 조성물 및 방법
US7582729B2 (en) * 2003-05-15 2009-09-01 The Rockefeller University Nucleic acids and polypeptides of C1 bacteriophage and uses thereof
US7569223B2 (en) 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
US7638600B2 (en) 2004-03-24 2009-12-29 The Rockefeller University Lytic enzymes and spore surface antigen for detection and treatment of Bacillus anthracis bacteria and spores
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
US8389469B2 (en) 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
CA2620903A1 (en) 2005-08-24 2007-03-01 The Rockefeller University Ply-gbs mutant lysins
IE20060488A1 (en) * 2006-06-29 2008-01-09 Teagasc Agric Food Dev Authori Recombinant staphylococcal phage lysin as an antibacterial agent
DE102006061002A1 (de) * 2006-12-22 2008-06-26 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von gram-positiven Bakterien
CA2706600A1 (en) * 2007-11-26 2009-06-04 Plant Bioscience Limited Novel polypeptides having endolysin activity and uses thereof
EP2103308A1 (de) * 2008-03-20 2009-09-23 PhytoLine GmbH Verfahren zur Herstellung eines Gemisches von Bakteriophagen und deren Verwendung für die Therapie von Antibiotika-resistenten Staphylococcen
US8840900B2 (en) 2008-07-03 2014-09-23 The Rockefeller University Chimeric bacteriophage lysin with activity against Staphylococci bacteria
AU2009273845B2 (en) * 2008-07-24 2016-02-04 The United State Of America, As Represented By The Secretary Of Agriculture Triple acting antimicrobials that are refractory to resistance development
GB0815484D0 (en) * 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
KR101016918B1 (ko) * 2009-01-08 2011-02-25 주식회사 인트론바이오테크놀로지 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질
CN103080307A (zh) * 2010-01-25 2013-05-01 美艾利尔斯卡保罗有限公司 A25噬菌体溶解酶
AU2012245391A1 (en) * 2011-04-21 2013-11-21 The Rockefeller University Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock

Also Published As

Publication number Publication date
NZ713076A (en) 2017-05-26
WO2012145630A2 (en) 2012-10-26
US11111484B2 (en) 2021-09-07
CA2833409A1 (en) 2012-10-26
US20230167427A9 (en) 2023-06-01
IL266476A (en) 2019-06-30
EP3252155A1 (en) 2017-12-06
IL271300A (en) 2020-01-30
MX2013012241A (es) 2014-05-07
AU2017202728A1 (en) 2017-05-18
MX2021007008A (es) 2022-06-02
MX370442B (es) 2019-12-13
US20220127590A1 (en) 2022-04-28
CN108578685A (zh) 2018-09-28
HK1247956A1 (zh) 2018-10-05
EP2699253A2 (en) 2014-02-26
US20200002694A1 (en) 2020-01-02
US20140072549A1 (en) 2014-03-13
JP6139509B2 (ja) 2017-05-31
EP2699253A4 (en) 2015-07-01
HK1244503A1 (zh) 2018-08-10
AU2019204660A1 (en) 2019-07-18
NZ731111A (en) 2019-06-28
AU2012245357B2 (en) 2017-06-08
JP6587655B2 (ja) 2019-10-09
US20200149025A1 (en) 2020-05-14
IL228869B (en) 2019-05-30
AU2012245357A1 (en) 2013-11-14
IL271300B (en) 2021-12-01
AU2019204660B2 (en) 2021-01-28
DK2699253T3 (en) 2018-07-16
US10544407B2 (en) 2020-01-28
US20220064615A1 (en) 2022-03-03
JP2014518849A (ja) 2014-08-07
MX336427B (es) 2016-01-18
JP2016147903A (ja) 2016-08-18
IL228869A0 (en) 2013-12-31
US11155799B2 (en) 2021-10-26
JP6284976B2 (ja) 2018-02-28
JP2017171686A (ja) 2017-09-28
CN103857410A (zh) 2014-06-11
EP2699253B1 (en) 2018-03-28
CN115887627A (zh) 2023-04-04
JP2019022504A (ja) 2019-02-14
CN107189997A (zh) 2017-09-22
US20150267185A1 (en) 2015-09-24
US9034322B2 (en) 2015-05-19
AU2017202728B2 (en) 2019-04-04
NZ616945A (en) 2015-11-27
IL266476B (en) 2020-01-30
US20170298334A1 (en) 2017-10-19
JP6735796B2 (ja) 2020-08-05
WO2012145630A3 (en) 2014-05-01
IL287530A (en) 2021-12-01
US9914915B2 (en) 2018-03-13

Similar Documents

Publication Publication Date Title
ES2682670T3 (es) Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
WO2018013583A3 (en) Medicinal vaginal lactobacillus cocktail
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
IN2014KN01713A (es)
IN2014KN01714A (es)
IN2014KN01716A (es)
GB201016733D0 (en) Compounds and their use
JP2015517488A5 (es)
RU2018121290A (ru) Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий
CO2017012454A2 (es) Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia
JP2017532343A5 (es)
WO2010123200A3 (ko) 병원성 장내세균을 사멸시키는 박테리오파지
MX2017008563A (es) Novedoso bacteriófago esc-cop-1 de e. coli tipo f18 productora de toxina shiga y su uso para inhibir la proliferación de e. coli tipo f18 productora de toxina shiga.
ES2955834T3 (es) Variantes de plantaricina nc8alphabeta
WO2018155813A3 (ko) 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2
WO2019045248A3 (ko) 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
MX2017016227A (es) Peptidos anti-infecciosos de amplio espectro.
MX2018008545A (es) Composicion antibacteriana y metodo para tratar infecciones por estafilococos con la composicion antibacteriana.
JP2013539776A5 (es)
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
NZ756128A (en) Novel peptides and analogs for use in the treatment of oral mucositis
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
NZ610400A (en) Antimicrobial protein
EA201892322A1 (ru) Способ лечения или предупреждения остеоартрита